WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Top Hunk! Tom Cruise, 61, proved he's still got it with THAT shirtless snapFaye Dunaway's wildest moments! Fiery OscarEMILY PRESCOTT: Emma Stone's got a black belt in red carpet appearancesCopper has careerChina adds 7 ski resorts to national rosterJude Bellingham is caught trying to put off England teamMotherland is BACK (sort of)! BBC announces spinLod, Jeong rally Minnesota United to 22 dead and 5 missing after a boat collision on the Danube River in HungaryChina's sci